In TCGA-BLCA, notable upregulations include GABRG2 with a fold change of 15.9, HTR2C at 5.2, and S1PR5 (Sphingosine-1-Phosphate Receptor 5) at 4.2, while significant downregulations are seen in CHRM2 (−49.8-fold), P2RX1 (−47.3-fold), and ADRB3 (−28.7-fold). Here, CHRM2 is linked to bladder transitional cell carcinoma.